Unsere Gruppe organisiert über 3000 globale Konferenzreihen Jährliche Veranstaltungen in den USA, Europa und anderen Ländern. Asien mit Unterstützung von 1000 weiteren wissenschaftlichen Gesellschaften und veröffentlicht über 700 Open Access Zeitschriften, die über 50.000 bedeutende Persönlichkeiten und renommierte Wissenschaftler als Redaktionsmitglieder enthalten.

Open-Access-Zeitschriften gewinnen mehr Leser und Zitierungen
700 Zeitschriften und 15.000.000 Leser Jede Zeitschrift erhält mehr als 25.000 Leser

Abstrakt

Need for Artificial Intelligence in Pharmaceutical Industry and its Limitations

Varun Pareek, Lokendra Sharma, Sushil Kumar

AI is often being touted as the means to bring about the fourth Industrial Revolution and its role in almost all sectors of our society is almost certain. This brings about an urgent need for evaluating benefits and limitations of AI and machine learning across various sectors. Pharmaceutical industry has pioneered in embracing the use of AI in all of its core areas but the success as of yet seems very limited. The major advantage of AI is that it reduces the time that is needed for drug development and, in turn, it reduces the costs that are associated with drug development, enhances the returns on investment and may even cause a decrease in cost for the end user along with improved drug safety. So in this article we will review the scope and limitations of AI in the pharmaceutical industry.